Podcast: US Biosimilars Regulation – What now for substitution / interchangeability?

We're pleased to announce a new content partnership with Datamonitor Healthcare. Each week they’ll be sharing their latest research and insights into the Biosimilars field! 
It's no surprise that Biosimilar manufacturers don’t want to take a risk. There are many potential barriers with the new legislation that aims to switch prescriptions from original Biologics to comparable Biosimilars. One possible disruption? Requiring the Pharmacist to notify the Physician within 24 hours of dispensing the product. So how do you get companies on board?

Tune in to the podcast below and listen to experts, John Hodgson - Managing Editor, SCRIP Intelligence and Rory Bligh - Analyst (Companies), Datamonitor Healthcare as they cover key issues regarding the new legislation and the future of Biosimilars.

Key topics include:

• What does this legislation mean for the future of the biosimilars market?
• How will it shape upcoming legislation and regulatory changes?
• What can we learn from similar legislation that has implemented across Europe

Want to learn more about Biosimilars? Join us for the 14th Annual Business of Biosimilars event, October 15-17 in Boston, MA. Visit our website to opt in for all updates regarding Biosimilars. We look forward to seeing you this fall!

Share this article with your social network, just click below to share now!

Share |